Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.46 |
| ▸ | CTSD | P07339 | 4/20 | 0.46 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630627 | 0.94 | ACE (0.49) | BACE1CTSDACERENNPY1R | |
| SCHEMBL31316151 | 0.90 | F2R (0.43) | BACE1CTSDACERENNPY1R | |
| SCHEMBL30512652 | 0.89 | NTSR2 (0.45) | NPY1RNPY2RNPY4RNPY5RNTSR2 | |
| SCHEMBL29839435 | 0.86 | ACE (0.44) | BACE1CTSDACERENNTSR2 | |
| SCHEMBL29805727 | 0.84 | CALCRL (0.46) | BACE1CTSDACERENF2 | |
| SCHEMBL32672659 | 0.84 | XIAP (0.50) | ACERENNPY1RNPY2RNPY4R | |
| SCHEMBL30435414 | 0.84 | ACE (0.51) | BACE1CTSDACERENF2 | |
| SCHEMBL30435255 | 0.84 | ACE (0.51) | BACE1CTSDACERENF2 | |
| SCHEMBL29823571 | 0.83 | XIAP (0.47) | ACERENNPY1RNPY2RNPY4R | |
| SCHEMBL2513001 | 0.83 | ACE (0.56) | ACERENF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | BACE1 530/4885CTSD 3399/4885ACE 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.